Endoscopic Evaluation of Lower Gastrointestinal Bleeding (GIB) in Patients Presenting With Melena

NCT ID: NCT00164723

Last Updated: 2015-08-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 165 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-02-28
• Study Completion Date: 2014-11-30

Brief Summary

To evaluate the incidence and etiology of small bowel or large bowel bleeding in patients presenting with melena.

Detailed Description

Although tarry stool is a common feature of peptic ulcer bleeding, it can also be a manifestation of lower gastrointestinal (GI) bleeding. Examples include colonic cancer, small bowel tumors, and small or large bowel ulcers induced by aspirin or painkillers (NSAIDs). However, clinicians are often misled by the finding of peptic ulcers as the source of GI bleeding. It is not uncommon to detect peptic ulcers incidentally but the source of bleeding is actually in the lower GI tract (e.g. NSAID- or aspirin-induced small or large bowel bleeding ulcers, small bowel tumors, or colorectal cancer). Delay in diagnosis of lower GI bleeding often leads to serious consequences.

The preferred investigations for lower GI bleeding are colonoscopy plus video capsule endoscopy. Colonoscopy has been the gold standard for the diagnosis of colonic bleeding. The risk of colonoscopy-induced complications such as bleeding or perforation is less than 1 in 3500. Video capsule endoscopy is a non-invasive, safe and accurate technology that has been approved by the FDA for investigation of small bowel diseases. The video capsule is an 11x 26mm capsule that encases a digital camera, light-emitting diodes, batteries, and a transmitter. The patient needs to swallow the video capsule after an overnight fast and wear a recording device for eight hours. Images are taken twice-per-second and transmitted to the recording device. Oral feeding can be resumed after four hours. There is no restriction to daily activities. The swallowed capsule will be expelled naturally after 5 to 12 hours virtually in all patients. The risk of capsule retention is very low and only occurs in patients with severe small bowel stricture.

This study aims to assess the incidence and etiology of lower GI bleeding in patients presenting with tarry stool. The result will provide important information about the magnitude of the problem of lower GI bleeding that will improve our patient care.

Conditions

Gastrointestinal Hemorrhage

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

NSAID

patients taking NSAID will undergo capsule endoscopy

Group Type: OTHER

Capsule endoscopy

Intervention Type: PROCEDURE

Capsule endoscopy and colonoscopy

Aspirin

patients taking Aspirin will undergo capsule endoscopy

Group Type: OTHER

Capsule endoscopy

Intervention Type: PROCEDURE

Capsule endoscopy and colonoscopy

Non-user

patients didn't take NSAID or ASA will undergo capsule endoscopy

Group Type: OTHER

Capsule endoscopy

Intervention Type: PROCEDURE

Capsule endoscopy and colonoscopy

Interventions

Capsule endoscopy

Capsule endoscopy and colonoscopy

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

Non-user group

Definition :

1. No continuous use of NSAIDs or aspirin for more than 1 week within the past 3 Months and patients who had not been exposed to NSAIDs, aspirin, or unknown drugs ≥ 4 weeks prior to GI bleed;

2. Clean base gastric or duodenal ulcer is required (i.e., patients with normal finding or erosions alone on OGD will not be eligible)

3. Age ³18;

4. Willing to meet the capsule endoscopy procedure requirements, and have provided written informed consent prior to admission to this study.

5. Concomitant clean base GU and DU can be recruited

Exclusion Criteria

The presence of any of the following will exclude a subject from study enrollment:

1. Hematemesis as the presenting symptom;

2. Gastroscopic findings accountable for the bleeding episode (i.e., presence of blood in the stomach, ulcers showing high-risk bleeding stigmata, bleeding gastroesophageal varices, Mallory-Weiss tear showing bleeding stigmata, portohypertensive gastropathy);

3. Gastroscopic findings are normal.

4. Uncontrolled bleeding requiring emergency surgery or mesenteric angiography;

5. Has cardiac pacemaker or other electromedical implant;

6. Is expected to undergo MRI examination or be in the vicinity of powerful electromagnetic fields between ingesting the capsule and its excretion;

7. Active malignancy or history of a malignancy within 5 years prior to enrollment;

8. Previous gastric surgery;

9. Known or suspected complete or partial stenosis of the small intestine;

10. Established delayed gastric emptying or diabetic gastroparesis;

11. Known inflammatory bowel disease;

12. Use of misoprostol within the 2 weeks prior to admission;

13. Concomitant use of NSAIDs and aspirin;

14. Currently taking anticoagulants or lithium;

15. Has a swallowing disorder that precludes safe ingestion of the capsule;

16. Pregnancy;

17. History of clinically significant substance abuse, drug addiction or a history of chronic ingestion of more than two alcoholic drinks per day;

18. Any mental or physical condition, which precludes compliance with study and/or device instructions;

19. Received any investigational medication within 30 days prior to the treatment period;

20. Currently participating in another clinical study that may affect the results of this study.

21. Ulcer > 2cm

22. clean base ulcer with grade C or D esophagitis

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Chinese University of Hong Kong

OTHER

Sponsor Role: lead

Responsible Party

Francis KL Chan

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Francis KL Chan, MD

Role: PRINCIPAL_INVESTIGATOR

CUHK

Locations

Endoscopy Center in Prince of Wales Hospital

Hong Kong (sar), , China

Countries

China

Other Identifiers

CE_GIB

Identifier Type: -

Identifier Source: org_study_id